Related Experiment Videos
In vivo study of xibornol on phagocyte functions
Abstract:
Polymorphonuclear leukocytes (PML) represent the first step of defense against bacteria and fungi. Since many antimicrobial drugs have been reported to inhibit phagocyte function, we tested the interference of xibornol, a new antimicrobial agent, on phagocyte functions, in order to evaluate its possible use in chronic respiratory diseases. In the patients treated with xibornol (500 mg every 8 h for 7 days) we did not find any modification in phagocytosis frequency (PMF), phagocytosis index (PHI), nitroblue tetrazolium (NBT), reduction frequency (NRF), microbicidal activity and neutrophil mobility of PML, before, during and after the end of therapy.
Insights
Xibornol, a novel antimicrobial, did not affect key polymorphonuclear leukocyte (PML) functions like phagocytosis or microbicidal activity in patients with chronic respiratory diseases. This suggests xibornol may be safe for use in these conditions.
Area of Science:
- Immunology
- Pharmacology
- Microbiology
Background:
- Polymorphonuclear leukocytes (PML) are crucial for innate immunity against bacterial and fungal infections.
- Some antimicrobial drugs can impair phagocyte functions, potentially complicating treatment for certain diseases.
- Chronic respiratory diseases often involve secondary infections, necessitating safe and effective antimicrobial agents.
Purpose of the Study:
- To investigate the impact of the novel antimicrobial agent xibornol on the functions of polymorphonuclear leukocytes (PML).
- To assess the safety and potential utility of xibornol in managing chronic respiratory diseases by evaluating its effect on immune cell activity.
Main Methods:
- A clinical study involving patients treated with xibornol (500 mg every 8 hours for 7 days).
- Evaluation of various PML functions including phagocytosis frequency (PMF), phagocytosis index (PHI), nitroblue tetrazolium (NBT) reduction frequency (NRF), microbicidal activity, and neutrophil mobility.
- Measurements were taken before, during, and after the treatment period.
Main Results:
- No significant modifications were observed in PMF, PHI, NBT reduction frequency (NRF), microbicidal activity, or neutrophil mobility of PML.
- These immune functions remained unchanged throughout the xibornol therapy and post-therapy period.
Conclusions:
- Xibornol treatment did not adversely affect essential polymorphonuclear leukocyte (PML) functions.
- The findings support the potential use of xibornol as a safe antimicrobial agent in the context of chronic respiratory diseases, as it does not seem to compromise the host's primary defense mechanisms.